---
title: Predicting relapse in acute lymphoblastic leukemia
date: '2024-08-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39216505/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240901181354&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Outcomes in adult and pediatric patients with acute lymphoblastic leukemia
  (ALL) have improved over successive generations due to rigorously conducted clinical
  trials and incorporation of novel therapeutic agents. Despite these advances, approximately
  20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve
  long-term remission with frontline chemotherapy protocols, mostly due to relapse.
  The ability to predict which patients with ALL are more likely to relapse ...
disable_comments: true
---
Outcomes in adult and pediatric patients with acute lymphoblastic leukemia (ALL) have improved over successive generations due to rigorously conducted clinical trials and incorporation of novel therapeutic agents. Despite these advances, approximately 20% of high-risk pediatric patients and 50% of adults with ALL will fail to achieve long-term remission with frontline chemotherapy protocols, mostly due to relapse. The ability to predict which patients with ALL are more likely to relapse ...